Introduction
The following sections are not intended to be a summary of the individual chapters within this supplement. Rather they are the salient learning points about Clostridium difficile infection. It is hoped that these points may serve as a basis with which to understand the risk factors, disease process, management and control of this increasingly reported infection.
Pathogenesis
Not all strains are equally virulent. The cellular mechanism of action of toxins A and B, the glucosylation of Rho family proteins, is identical. There is inter-strain heterogeneity of toxin A and B gene sequences. Strains producing only toxin B have been detected. Much of the pathology may be immunopathology resulting from the action of recruited neutrophils. Some individual adults may be naturally immune to the actions of toxin A. There is evidence that gut mucus glycopeptides are chemoattractants for C. difficile. Toxin B may cause diarrhoea in humans.
Diagnosis
Stools for toxin assay should be tested fresh or stored at 4°C before testing. Optimum laboratory investigations include toxin assay and culture on diarrhoeic stools only. An alternative strategy involves storage of toxinpositive stools at 4°C or -20°C for later culture for outbreak investigation if necessary. Quality-controlled cultural methods must be in place before culture is attempted. Commercial kits that detect both toxins A and B have an advantage over those that detect toxin A alone.
Epidemiology and typing
The population in the community may be exposed to C. difficile from a variety of environmental sources but the diseased human gut is the most important reservoir. Epidemiological investigations can be adequately performed by a number of typing methods although standardization will be achieved best by a molecular typing method, probably based on PCR ribotyping. Carriage of strains from the community into the hospital may result in sporadic cases of C. difficile-associated diarrhoea. Surveillance data from hospitals in England and Wales shows that one PCR ribotype of C. difficile is present in 33 of 58 hospitals and accounts for 57% of all isolates submitted for typing. Strains originating from the environment and patients in the community are more diverse than those commonly causing hospital infection. Identical types of C. difficile may be found in the UK, Belgium, USA and Australia. Toxin A-negative/toxin B-positive strains are responsible for 3% of the strains received for typing in England and Wales. Phenotypic typing methods dependent on cell surface properties correlate well with one another. Strains of the same serogroup can be differentiated into distinct genotypes.
Clinical impact and cost
Toxin-producing C. difficile is the commonest identifiable cause of nosocomial diarrhoea. The elderly are the main susceptible patient group. Although carriage rates are high in neonates, disease incidence is extremely low. Other at-risk patients include the immunosuppressed and those undergoing gastro-intestinal surgery, with severe underlying disease or with a long hospital stay.
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The annual cost of C. difficile infection to an averagesized district general hospital has been calculated to be approximately £400,000, which includes 2100 lost bed days.
Antibiotics
Previous antibiotic therapy is the main risk factor. Cephalosporins and aminopenicillins are the most frequently cited causes of C. difficile infection. Aminoglycosides, fluoroquinolones and ureidopenicillins have a low propensity to induce C. difficile infection. The most successful single control measure to reduce symptomatic disease is antibiotic restriction. Antibiotic policies need to be policed and reviewed continually.
Treatment
Approximately a quarter of initial symptomatic episodes will resolve spontaneously. Metronidazole and vancomycin are similarly effective and the former is the antibiotic of choice when specific treatment is required. The majority of symptomatic recurrences of C. difficile infection are due to reinfection (with new strains) rather than relapse. New treatments are required which address the continued heightened susceptibility of some patients to C. difficile.
Biotherapeutic approaches to treatment are attractive concepts but are largely unsubstantiated. Brewer's yeast and Saccharomyces boulardii preparations cannot be assumed to be equivalent. Immunological treatment and preventative approaches require further evaluation.
Infection control
C. difficile spores may survive for months/years and are often widely distributed in the ward setting. Symptomatic patients should be isolated to reduce the dissemination of C. difficile. Approximately a quarter of patients who symptomatically respond to treatment still have C. difficile (culture or toxin)-positive faeces. There is no rationale for the continued isolation of asymptomatic individuals. There is a paucity of studies on both hand and environmental disinfection for the removal of C. difficile. The current recommendation is for handwashing with soap and water. Compliance with handwashing is often poor without repeated reinforcement. The most important factors governing the efficacy of environmental disinfection are probably the frequency and thoroughness of cleaning. Routine environmental decontamination is usually detergent-based, with hypochlorite preparations reserved for faecal spillages.
